Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05369481
Other study ID # Male Androgenic Alopecia
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 1, 2022
Est. completion date September 1, 2022

Study information

Verified date May 2022
Source Al-Azhar University
Contact Yassir Hagag, MBBCH
Phone +201021121721
Email yassir_hagag@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Androgenetic alopecia (AGA) is hair loss with specific clinical pattern, It Is characterized by follicular miniaturization, which occurs due to systemic androgens and genetic factors. Prevalence differs according to ethnic groups. It is more common and more severe in white men than in Asian and black men. The incidence increases with age. According to Hamilton's study, the prevalence is 30% in men at the age of 30, and 50% in the age of 50. Generally, the age of onset is the 3rd and 4th decade.


Description:

Androgenetic alopecia may affect self-esteem and quality of life in several affected individuals. There are two FDA-approved drugs for pattern baldness: topical minoxidil and finasteride, both of which require at least a 4- to 6-month trial before noticing improvement and must be used indefinitely to maintain a response. As such, medication adherence often can be poor. Furthermore, initiation of the drug may cause an initial shedding phase. Minoxidil was the first and, so far, the only topical product that has been FDA approved for the treatment of AGA. Minoxidil was originally developed as an oral medication for hypertension. Hypertrichosis was found in 24-100 % of patients treated with oral minoxidil, which led to the treatment of AGA with topical minoxidil. Androgenic Alopecia is caused by the overproduction of 5αdihydrotestosterone (5α-DHT), a potent androgen within the hair follicle, specifically the dermal papilla (DP) cells that are the main regulators of hair growth and are the only site of 5α-DHT action. Sildenafil is a selective inhibitor of phosphodiesterase 5 and was originally developed as an anti-anginal drug due to its vasodilatory and antiplatelet coagulation properties. Sildenafil enhances the proliferation of human dermal papilla cells and up-regulates the mRNA expression of vascular endothelial growth factor and platelet-derived growth factor (PDGF) which are responsible for hair growth. Topical sildenafil 1% has been used in the treatment of male androgenic alopecia.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date September 1, 2022
Est. primary completion date August 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Subjects clinically and dermoscopic diagnosed with AGA. - Age ranges from 18 to 45 years old. - Males - Willingness to provide pictures and follow-up studies. Exclusion Criteria: - Patients who received any topical or systemic treatment for AGA during the last 6 months, - Patients who had other types of alopecia such as alopecia areata, alopecia totalis, telogen effluvium, anagen effluvium, and acquired cicatricial alopecia. - Patients with anemia, thyroid disease, and vitamin D deficiency, - Any autoimmune disease or chronic debilitating disease (chronic renal failure, congestive heart failure, hepatic patients, cancer patients).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sildenafil 2%
Patients with male androgenic alopecia will be given topical Sildenafil 2% to apply twice daily for 6 consecutive months and then follow up.
Minoxidil 5 %
Patients with male androgenic alopecia will be given topical Minoxidil 5 % to apply twice daily for 6 consecutive months and then follow up.

Locations

Country Name City State
Egypt AL-Azhar University Hospital Cairo

Sponsors (1)

Lead Sponsor Collaborator
Mohammed Abd El Mawgoud Amer

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement changes improvement will be assessed by comparing the trichoscopic photos before and after treatment as regard hair density 6 months
Secondary Patient's satisfaction by asking the patients and changes in dermatology life Quality Index score as it reflects the quality of life related to skin manifestations 6 months
Secondary Complications infection and bleeding 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT06110377 - MALE HAIR LOSS - Treatment With Dutasteride Mesotherapy x Dutasteride MMP Technique (Injections With Tattoo Machine) Phase 4
Recruiting NCT05611593 - Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia Phase 1
Completed NCT03676400 - Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia N/A
Recruiting NCT05938569 - Computer-Assisted Hair Restoration Study Using ARTAS System N/A
Not yet recruiting NCT06326359 - Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia N/A
Recruiting NCT05426629 - Hydraderm for Androgenic Alopecia Phase 4
Recruiting NCT05827991 - A Clinical Observation of 1565nm Non-ablative Fractional Laser in the Treatment of Androgenic Alopecia N/A
Not yet recruiting NCT06292533 - Effectiveness of Ultrapulse for the Treatment of Androgenic Alopecia Among Malaysian: A Quasi-experimental Study N/A
Completed NCT02824380 - Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia Phase 1
Completed NCT06112782 - Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality N/A
Completed NCT02594046 - The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia N/A
Recruiting NCT05435625 - Fractional Laser Versus Radiofrequency in Androgenetic Alopecia N/A
Completed NCT05450861 - Effect of the Composition From Fish on Promoting Hair Growth N/A
Completed NCT03506503 - Condensed Nanofat Grafting for Treatment of Androgenetic Alopecia N/A
Completed NCT03467412 - To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin Phase 2
Completed NCT01852487 - Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia N/A
Not yet recruiting NCT03474718 - Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia Early Phase 1
Active, not recruiting NCT02914587 - Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study N/A
Completed NCT04341363 - Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling N/A
Completed NCT04450602 - A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss N/A